Saturday, 30 March 2013

Parodontax : For people who see blood when they brush

Brand : Parodontax
Company : GSK Consumer Healthcare

Brand Analysis Count : # 521


After the success of Sensodyne, GSK has launched another specialist toothpaste in the Rs 6000 crore Indian toothpaste market. While Sensodyne was a specialist for sensitive teeth, the new launch is in the gum-care category. GSK launched its global niche brand Parodontax recently in the Indian market.
The emergence of the niche products like sensitive , gum-care shows the new phase of the evolution of  Indian toothpaste market. According to ET, Sensodyne which was launched two years back is already a Rs 100 crore brand in India. The niche segments are growing at a faster pace than the core segment and marketers are rushing to cash in on this evolution.

Parodontax is a gum-care specialist. The brand is targeting those who are already suffering from bleeding gums. According to newspaper reports, the incidents of gum-related issues is as high as 33% which itself is a huge market waiting to be tapped.
The brand is now promoting awareness about the gum-related issues and advising customers to take bleeding gums seriously. The brand is now running its standard global TVC in the Indian market.

Not to be left behind , the market leader- Colgate has already launched its Pro-gum variant -Colgate Total Pro-gum health . The leader was quick to spot the threat of this GSK to its stronghold in the Indian market. Sensodyn has infact created a dent in the market position of Colgate. Pepsodent also has Pepsodent Sensitive and Pepsodent -G for the sensitive and gum-care segment respectively. Bu the share of noise of Pepsodent is abysmally low in these segments and I feel that Pepsodent has lost out in the race atleast for now.
Alries and Jack Trout had argued that line-extensions tend to be less effective when fighting specialist brands. Here the market leaders are fighting the specialist brands using variants. It remains to be seen how effective these defense would be .

No comments:

Post a Comment